occur during this window of time when central sensitisation is present. [1] [2] [3] [4] [5] Effective early acute treatment of a migraine might thus prevent subsequent migraines that would have occurred during this window of central sensitisation if the original migraine had not been terminated early, preventing both central sensitisation and subsequent migraines.
Diagnostic criteria
The international classification of headache disorders 6, 7 was revised after this trial had begun. When the revised diagnostic criteria were applied to participants, all participants received a diagnosis of migraine by the revised diagnostic criteria. The 14 participants who recorded 15-20 headache days per 30 days also received the migraine sub-diagnosis of chronic migraine in the revised international classification of headache disorders, whereas participants who recorded fewer headache days per month (n=218) received a sub-diagnosis of episodic migraine. 7 The former 14 participants were distributed as follows: two in the optimised acute treatment plus β blocker group, three in the optimised acute treatment plus placebo group, three in the optimised acute treatment plus behavioural migraine management and placebo group, and five in the optimised acute treatment plus behavioural migraine management and β blocker group.
The criterion of 15 headache days for the sub-diagnosis of chronic migraine is not empirically based and may present a moving target (the Classification Committee at the International Headache Society may change the threshold). The Classification Committee selected this criterion, in part, so it would match the 15 day criterion for the sub-diagnosis of chronic tension-type headache that was already in the diagnostic and classification system. To our knowledge, no empirical evidence suggests that people with a diagnosis of migraine who have a few less or a few more than 15 headache days in one particular month differ in response to treatment.
Dropout rates
Recent clinical trials of preventive migraine drugs have reported about a 50% drop out of randomised participants at six months, [8] [9] [10] compared with the dropout rate in the Treatment of Severe Migraine trial of about 35% at 10 months. Another way to compare dropout rates is to say that the dropout rate of about 50% at 16 months in the TSM trial is similar to the dropout rate at six months in these recent trials.
